SLC5A2 and coronary artery disorder: Recent clinical trials, including CVD-REAL Nordic (35), EMPA-REG OUTCOME (36–38), and the CANVAS project (39, 40), confirmed the effectiveness of SGLT2 inhibitors in patients with coronary heart disease.